Regeneron Pharmaceuticals Inc (NAS:REGN)
$ 714.47 -0.66 (-0.09%) Market Cap: 78.51 Bil Enterprise Value: 71.42 Bil PE Ratio: 17.68 PB Ratio: 2.68 GF Score: 88/100

Regeneron Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript

Mar 16, 2022 / 12:00PM GMT
Release Date Price: $677.98 (+1.81%)
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Okay. Good morning, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, Senior Biopharma Analyst here at Barclays. I'm pleased to welcome Regeneron Pharmaceuticals on the stage. It's been a while since we've seen you guys in person, really glad to have you. We have both Marion McCourt, EVP of Commercial; and Bob Landry, CFO.

Before we jump into the questions here, Bob is going to make some opening remarks and some forward-looking statements.

Robert E. Landry
Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO

Yes. Great. Carter, thank you for inviting us. And again, a little surreal for Marion and myself to be on stage after 2-plus years. Thanks just to certainly give it a go and get into Q&A.

So from a forward-looking statement point of view, I'd like to remind everybody that the statements Marion and I will be making today about Regeneron contain risks and uncertainties. And again, I encourage everyone to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot